Restarting a GLP-1 After a Break

Treatment does not always run in an unbroken line. Pharmacies run short, surgeries and illnesses put medications on pause, budgets and insurance decisions interrupt, and some people simply need a deliberate stop. Whatever the reason, the situation you are left with is the same one: weeks have passed since your last dose, and the question is no longer what to do about a late shot. It is how to begin again.

That question has a real answer, but it lives with your prescriber, not in an article. What this article can do is make the conversation an informed one: what the prescribing information actually says about interrupted treatment, what a multi-week gap does to the medication still in your body, why prescribers sometimes restart partway down the ladder, and exactly which facts to bring to the appointment.

A few days and a few weeks are different questions

The missed dose guidance that comes with these medications is written for short slips. Each label defines a window: per the prescribing information, a missed Ozempic dose can be taken within five days, and a missed Mounjaro or Zepbound dose within four. Inside those windows, the answer is a matter of timing, and we collected the rules for every medication in the class in Missed Your GLP-1 Dose? What the Official Guidance Says.

A gap of several weeks is a different animal. The missed dose sections of the Ozempic, Mounjaro and Zepbound labels cover windows much shorter than the gap you have, so they are not the right tool for this question, and we will not stretch them to pretend otherwise. Once weeks have passed, the situation is no longer a late dose. It is an ended course of treatment that may be followed by a new one, and the person who decides what that new course looks like is the one who prescribed the first.

That framing is worth internalizing before the appointment, because it changes the question you ask. Not what is the rule for a missed dose, but how should I begin again, given how long I have been off and how I tolerated it before. It is a better question, and it is the one your prescriber can actually answer.

What the labels say about restarting

Two products in this class carry explicit language about interrupted treatment. The Wegovy label addresses repeated misses directly: if two or more consecutive doses are missed, dosing can resume as scheduled or, if needed, be reinitiated following the dose escalation schedule. The practical summary of that guidance is to call your prescriber, who may restart titration. Note what the label does not do: it does not pick between the two options for you. It hands the decision to the clinician, with the dose escalation schedule available as one of the paths.

Saxenda, the daily injection, has its own version: if more than three days are missed, the prescribing information says the prescriber may restart treatment at 0.6 mg, the bottom of its ladder. Again, that is language for your prescriber to act on, not an instruction aimed at you.

What about the rest? We will not put restart instructions in the mouths of labels that do not contain them. The Ozempic, Mounjaro and Zepbound missed dose sections, as above, cover shorter windows, and a multi-week gap on any of them is a prescriber conversation in the plainest sense: there is no label sentence to lean on, so the plan gets built by a person instead.

GLP 1 Tracker AppReal dose ladders with automatic week counts, so the story of your treatment, gaps included, is one your prescriber can read in seconds. Get the app

What a multi-week break does to medication levels

Understanding the restart question starts with knowing what is left in your system, and that comes down to half-lives. Semaglutide, the molecule in Ozempic and Wegovy, has a half-life of about a week. Tirzepatide, in Mounjaro and Zepbound, has one of about five days. The half-life is the time it takes for the amount in your body to fall by half, then half again, and so on, in a long fading tail. The commonly taught rule of thumb is that a medication is largely cleared after about four to five half-lives.

Run that math on a multi-week gap and the picture is clear. For semaglutide, four to five half-lives is roughly a month; for tirzepatide it is a few weeks. So after several weeks without a dose, you are close to where you were before the first injection ever went in: not precisely zero, but close enough that the distinction stops mattering. We walked through this arithmetic in more detail in Semaglutide Half-Life: Understanding Your Medication Level.

During treatment, that same slowness is what makes weekly dosing work at all: each shot rides on the tail of the previous ones, and levels build toward a steady state. A long break is that machinery running in reverse. The accumulated level you spent months building drains away on the same timeline it arrived on.

Why tolerance may not carry over

Here is the reason clinicians commonly give for caution around restarts, offered as an explanation and not as an instruction. The dose ladders on these medications exist largely for one purpose: letting the digestive system adjust gradually. Each step up raises the medication level a little, the body adapts, and the stomach effects that mark the early weeks, mostly nausea, tend to settle as it does. Climbing the ladder is, in part, the process of building that tolerance.

Now run the break forward again. Over several weeks the medication largely clears, and the adaptation built during the climb may fade along with it. The body that handled a higher rung comfortably last spring may not be the same body, in this specific respect, that faces the first dose after a summer away. This is not a certainty; it is a commonly given reason, and prescribers weigh it against everything else they know about your case.

It does explain, though, why the Wegovy label offers reinitiation following the dose escalation schedule as one of its two paths, and why a prescriber looking at a long gap might reach for it. Some people also report that the early weeks after a restart echo their very first weeks on the medication, which fits the same general picture. The choice among paths stays where it belongs: in the prescriber's office, made with your actual history in hand.

The three questions a prescriber will ask

Whatever the medication and however long the gap, the restart conversation tends to open with the same three questions, and all three are answerable from a dose log in seconds:

• When was your last dose? The single most important data point, and the one memory is worst at. A log gives the date without reconstruction.
• What rung of the ladder were you on? The step you had reached, which is context for everything from tolerance history to what restarting might involve. On a log built with real titration ladders, this is simply the dose history.
• How long has the gap been? Which, combined with the first answer, tells the prescriber how much medication can plausibly remain, using the half-life math above.

Beyond the three questions, tolerance history matters too: how you felt at each step, what side effects came and went, whether the climb was smooth or rough. That is a longer conversation, and the general playbook for it is in Make Your Next Appointment Count: Bringing Data to the Doctor. The short version is that a dated record turns I think I was on the middle dose, and it went okay into an answer a prescriber can act on.

If a supply gap caused the break

One cause of multi-week breaks deserves its own mention, because it changes what happens after the conversation. If the interruption was a shortage or a pharmacy that could not fill your prescription, restarting is partly a logistics problem: when supply returns, whether your prescription still stands, and how to avoid landing in the same gap again. People also sometimes stretch doses to make a pen last during a shortage, which is worth discussing with a pharmacist or prescriber rather than improvising. We covered the whole supply-side playbook, including what tracking helps with during a gap, in Medication Shortages: Tracking Through Supply Gaps.

The other causes, surgery, illness, cost, a deliberate pause, are less about logistics and more about timing and plan, but they end at the same place: a prescriber who knows the reason for the break, the length of it, and where you left off.

Restart day, and after

Once your prescriber has given you a plan, the work returns to the kind of tracking that filled the first months of treatment. Log the first dose of the new stretch like any other: the date, the dose as prescribed, and a short note on the entry if there is context worth keeping, such as that this is a restart after a known gap. If the plan involves the dose escalation schedule, the week counts at each step matter again, exactly as they did the first time through.

Two rules survive every scenario, and they are short. Never take a double dose to make up for lost time; no gap, however long, makes two doses at once safe. And never let an article, an app or a well-meaning friend choose the restart dose; that choice is the entire content of the prescriber conversation this article keeps pointing you toward.

Before you restart, look backLast dose date, ladder step, gap length: your dose log answers the questions your prescriber is about to ask. Download